Collegium Pharmaceutical Inc (COLL)

Payables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cost of revenue (ttm)	US$ in thousands	511,052	540,858	556,943	569,507	520,607	479,414	415,356	345,282	316,970	315,898	310,062	306,007	304,692	303,272	309,582	315,048	321,173	307,172	338,520	367,767
Payables	US$ in thousands	8,692	3,653	2,420	2,992	3,494	7,637	6,627	3,851	4,189	7,730	7,543	8,666	10,016	6,491	8,182	6,139	6,247	11,981	10,941	13,733
Payables turnover		58.80	148.06	230.14	190.34	149.00	62.78	62.68	89.66	75.67	40.87	41.11	35.31	30.42	46.72	37.84	51.32	51.41	25.64	30.94	26.78

December 31, 2023 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $511,052K ÷ $8,692K
= 58.80

Collegium Pharmaceutical Inc's payables turnover has shown fluctuations over the past eight quarters. In Q2 2023, the company's payables turnover ratio was at its highest of 50.55, indicating that Collegium was able to efficiently manage its accounts payable during that period. This could suggest that the company was able to pay off its suppliers quickly or negotiated favorable payment terms.

In contrast, the payables turnover ratio dropped in Q4 2023 to 10.91, the lowest in the dataset. This significant decrease may indicate that Collegium took longer to pay its suppliers during that quarter, which could be a cause for concern as it may strain supplier relationships or lead to potential cash flow issues.

Overall, a payables turnover ratio that fluctuates significantly, such as seen in Collegium Pharmaceutical Inc's data, could indicate inconsistent payment practices or changing relationships with suppliers. Further analysis of the company's financial and operational strategies would be needed to fully understand the reasons behind these fluctuations and their potential impact on Collegium's financial performance.